BioCentury | Dec 1, 2017
Clinical News

Critical Outcomes expands Phase I COTI-2 study to HNSCC

...PKBA) phosphorylation in Phase I testing for gynecological malignancies (see BioCentury, Feb. 22, 2016 ). Critical Outcome Technologies Inc....
...pharmacokinetics, clinical activity and response duration Status: Phase I started Milestone: Phase I data (2018) Allison Johnson COTI-2 Critical Outcome Technologies Inc. Protein...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

...EGFR ; ErbB1 ; HER1), to treat colorectal cancer and head and neck cancer. Critical Outcome Technologies Inc....
BioCentury | May 31, 2017
Distillery Therapeutics

Pulmonary

...L-aptamer MCP-1 inhibitor developed using Spiegelmer technology, in Phase I testing to treat solid tumors. Critical Outcome Technologies Inc....
BioCentury | Apr 13, 2017
Distillery Therapeutics

Cancer

...which acts on an unknown target, to treat inflammatory bowel disease (IBD) and rheumatoid arthritis. Critical Outcome Technologies Inc....
BioCentury | Jun 13, 2016
Financial News

Critical Outcome Technologies completes warrant exercise

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2016-06-03 Type: Warrant exercise Raised: C$1.6 million ($1.3 million) Shares: 5.8 million Shares after offering: 152.3 million Investor: Existing investors WIR...
BioCentury | Feb 22, 2016
Clinical News

COTI-2: Phase I started

...for 5 consecutive days followed by 2 days off treatment every week in 4-week cycles. Critical Outcome Technologies Inc....
BioCentury | Aug 10, 2015
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2015-08-04 Type: Private placement of units Raised: C$836,560 ($636,622) Units: 2.8 million Price: C$0.30 (unit) Shares after offering: 122 million Note:...
BioCentury | Feb 23, 2015
Financial News

Critical Outcome Technologies Inc completes private placement of units

Critical Outcome Technologies Inc . (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2015-02-18 Type: Private placement of units Raised: C$542,990 ($436,510) Units: 2.1 million Price: C$0.26 (unit) Shares after offering: 117.5 million Note:...
BioCentury | Dec 8, 2014
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2014-11-26 Type: Private placement of units Raised: $702,420 Units: 3.1 million Price: $0.23 (unit) Shares after offering: 113.9 million Note: The...
BioCentury | Nov 17, 2014
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2014-11-07 Type: Private placement of units Raised: $1.2 million Units: 5.1 million Price: $0.23 (unit) Shares after offering: 110.9 million Note:...
Items per page:
1 - 10 of 57
BioCentury | Dec 1, 2017
Clinical News

Critical Outcomes expands Phase I COTI-2 study to HNSCC

...PKBA) phosphorylation in Phase I testing for gynecological malignancies (see BioCentury, Feb. 22, 2016 ). Critical Outcome Technologies Inc....
...pharmacokinetics, clinical activity and response duration Status: Phase I started Milestone: Phase I data (2018) Allison Johnson COTI-2 Critical Outcome Technologies Inc. Protein...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

...EGFR ; ErbB1 ; HER1), to treat colorectal cancer and head and neck cancer. Critical Outcome Technologies Inc....
BioCentury | May 31, 2017
Distillery Therapeutics

Pulmonary

...L-aptamer MCP-1 inhibitor developed using Spiegelmer technology, in Phase I testing to treat solid tumors. Critical Outcome Technologies Inc....
BioCentury | Apr 13, 2017
Distillery Therapeutics

Cancer

...which acts on an unknown target, to treat inflammatory bowel disease (IBD) and rheumatoid arthritis. Critical Outcome Technologies Inc....
BioCentury | Jun 13, 2016
Financial News

Critical Outcome Technologies completes warrant exercise

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2016-06-03 Type: Warrant exercise Raised: C$1.6 million ($1.3 million) Shares: 5.8 million Shares after offering: 152.3 million Investor: Existing investors WIR...
BioCentury | Feb 22, 2016
Clinical News

COTI-2: Phase I started

...for 5 consecutive days followed by 2 days off treatment every week in 4-week cycles. Critical Outcome Technologies Inc....
BioCentury | Aug 10, 2015
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2015-08-04 Type: Private placement of units Raised: C$836,560 ($636,622) Units: 2.8 million Price: C$0.30 (unit) Shares after offering: 122 million Note:...
BioCentury | Feb 23, 2015
Financial News

Critical Outcome Technologies Inc completes private placement of units

Critical Outcome Technologies Inc . (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2015-02-18 Type: Private placement of units Raised: C$542,990 ($436,510) Units: 2.1 million Price: C$0.26 (unit) Shares after offering: 117.5 million Note:...
BioCentury | Dec 8, 2014
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2014-11-26 Type: Private placement of units Raised: $702,420 Units: 3.1 million Price: $0.23 (unit) Shares after offering: 113.9 million Note: The...
BioCentury | Nov 17, 2014
Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario Business: Cancer, Autoimmune, Infectious Date completed: 2014-11-07 Type: Private placement of units Raised: $1.2 million Units: 5.1 million Price: $0.23 (unit) Shares after offering: 110.9 million Note:...
Items per page:
1 - 10 of 57